Phase 1 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 80 years old, of any gender
• People diagnosed with advanced clear cell renal cell carcinoma (a type of kidney cancer) or tumors linked to a condition called von Hippel-Lindau (VHL) Syndrome
• People who are generally well enough to carry out light activity or desk work, but may not be able to do heavy physical work (this is measured by a standard scale called ECOG, scores 0–1)
• People expected to live for at least 12 weeks
• People willing to use adequate birth control measures throughout the study
• Women who are not pregnant at the time of screening
• People who are able to understand and sign a written consent form before the study begins

Who may not be able to join:

• People who have recently received certain treatments, including: hypoxia-inducible factor (HIF) inhibitors; traditional Chinese medicines used for tumours within the past 2 weeks; chemotherapy, experimental drugs, or other systemic anti-tumour therapies within the past 3 weeks; colony-stimulating factor injections within the past 4 weeks; local radiation therapy within the past 2 weeks, or extensive bone marrow or large-area radiation within the past 4 weeks; or major surgery within the past 4 weeks
• People whose blood oxygen levels measured by a fingertip monitor were below 92% at screening, or who need extra oxygen either sometimes or continuously
• People who have not yet recovered from significant side effects (grade 2 or higher) caused by a previous cancer treatment
• People who have, or have had, another type of cancer not related to VHL Syndrome
• People with poor bone marrow function or significant problems with how their organs (such as the liver or kidneys) are working
• People who have had a significant bleeding event or a tendency to bleed heavily in the month before starting the study
• People who have had a serious infection in the 4 weeks before starting the study
• People with digestive system conditions that could affect how the study drug is absorbed, broken down, or removed by the body
• People with a history of severe allergic reactions, or who are known to be allergic to the study drug (HS-10516) or its breakdown products
• People with any other disease or condition that the study doctor believes could put them at risk or affect the reliability of the study results

Important: Always verify eligibility with the trial site directly before applying.